Biotech stocks can be risky buys as they're often unprofitable and it may be years before they start generating positive cash flow. But one stock that may be a bit safer these days is Axsome Therapeutics (NASDAQ: AXSM).

Although it remains unprofitable, sales have been growing. The company has a couple of promising assets in its portfolio and there's reason for optimism that its financials will be stronger in the future. Has the stock become a no-brainer buy?

A big risk when investing in biotech stocks is that the underlying businesses are bleeding cash and wildly unprofitable, since they aren't generating much -- if any -- revenue in their early stages.

Continue reading

Source Fool.com